Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/168554
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Paiva, Bruno | - |
dc.contributor.author | Mateos, Maria Victoria | - |
dc.contributor.author | Sánchez-Abarca, Luis Ignacio | - |
dc.contributor.author | Puig, Noemi | - |
dc.contributor.author | Vidriales, Maria Belén | - |
dc.contributor.author | López-Corral, L. | - |
dc.contributor.author | Corchete, Luis A. | - |
dc.contributor.author | Hernandez, Miguel T. | - |
dc.contributor.author | Bargay, Joan | - |
dc.contributor.author | Arriba, Felipe de | - |
dc.contributor.author | Rubia, Javier de la | - |
dc.contributor.author | Teruel, Ana-Isabel | - |
dc.contributor.author | Giraldo, Pilar | - |
dc.contributor.author | Rosiñol, Laura | - |
dc.contributor.author | Prósper, Felipe | - |
dc.contributor.author | Oriol, Albert | - |
dc.contributor.author | Hernández, José | - |
dc.contributor.author | Esteves, Graça | - |
dc.contributor.author | Lahuerta, Juan José | - |
dc.contributor.author | Bladé, Joan | - |
dc.contributor.author | Pérez-Simón, José A. | - |
dc.contributor.author | San Miguel, Jesús F. | - |
dc.date.accessioned | 2018-08-10T09:27:50Z | - |
dc.date.available | 2018-08-10T09:27:50Z | - |
dc.date.issued | 2016 | - |
dc.identifier | doi: 10.1182/blood-2015-10-662320 | - |
dc.identifier | issn: 0006-4971 | - |
dc.identifier | e-issn: 1528-0020 | - |
dc.identifier.citation | Blood 127(9): 1151-1162 (2016) | - |
dc.identifier.uri | http://hdl.handle.net/10261/168554 | - |
dc.description | On behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups. | - |
dc.description.abstract | There is significant interest in immunotherapy for the treatment of high-risk smoldering multiple myeloma (SMM), but no available data on the immune status of this particular disease stage. Such information is important to understand the interplay between immunosurveillance and disease transformation, but also to define whether patients with high-risk SMM might benefit from immunotherapy. Here, we have characterized T lymphocytes (including CD4, CD8, T-cell receptor γδ, and regulatory T cells), natural killer (NK) cells, and dendritic cells from 31 high-risk SMM patients included in the treatment arm of the QUIREDEX trial, and with longitudinal peripheral blood samples at baseline and after 3 and 9 cycles of lenalidomide plus low-dose dexamethasone (LenDex). High-risk SMM patients showed at baseline decreased expression of activation-(CD25/CD28/CD54), type 1 T helper-(CD195/interferon-γ/tumor necrosis factor-α/interleukin-2), and proliferation-related markers (CD119/CD120b) as compared with age-matched healthy individuals. However, LenDex was able to restore the normal expression levels for those markers and induced a marked shift in T-lymphocyte and NK-cell phenotype. Accordingly, high-risk SMM patients treated with LenDex showed higher numbers of functionally active T lymphocytes. Together, our results indicate that high-risk SMM patients have an impaired immune system that could be reactivated by the immunomodulatory effects of lenalidomide, even when combined with low-dose dexamethasone, and support the value of therapeutic immunomodulation to delay the progression to multiple myeloma. | - |
dc.description.sponsorship | This study was supported by the Cooperative Research Thematic Network grants RD12/0036/0058 and RD12/0043/0012 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370; G03/136; and Sara Borrell: CD13/00340); Asociación Española Contra el Cáncer (GCB120981SAN), Spain; and a European Research Council 2015 Starting Grant (B.P.). | - |
dc.publisher | American Society of Hematology | - |
dc.rights | closedAccess | - |
dc.title | Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1182/blood-2015-10-662320 | - |
dc.date.updated | 2018-08-10T09:27:50Z | - |
dc.description.version | Peer Reviewed | - |
dc.language.rfc3066 | eng | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.contributor.funder | Asociación Española Contra el Cáncer | - |
dc.contributor.funder | European Research Council | - |
dc.contributor.funder | Red Temática de Investigación Cooperativa en Cáncer (España) | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000781 | es_ES |
dc.identifier.pmid | 26668134 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairetype | artículo | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
45
checked on 07-abr-2024
SCOPUSTM
Citations
61
checked on 21-abr-2024
WEB OF SCIENCETM
Citations
64
checked on 27-feb-2024
Page view(s)
362
checked on 24-abr-2024
Download(s)
78
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.